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Abstract
Backgroud: Interleukin-10(IL-10) is a multifunctional cytokine with both immunosuppressive and antiangiogenic 
functions. Polymorphisms in the IL-10 gene promoter genetically determine interindividual differences in IL-10 
production. This study was performed to determined whether polymorphisms in the IL-10 gene promoter were 
associated with breast cancer in a Chinese Han population.
Methods: We genotyped 315 patients with breast cancer and 322 healthy control subjects for -1082A/G, -819T/C and -
592A/C single nucleotide polymorphisms in the promoter region of the IL-10 gene by polymerase chain 
reactionerestriction fragment length polymorphism (PCR-RFLP).
Results: There were no significant differences in genotype, allele, or haplotype frequencies in all three loci between 
patients and healthy controls. Analysis of breast cancer prognostic and predictive factors revealed that the -1082AA 
genotype was associated with a significantly increased risk of lymph node (LN) involvement (P = 0.041) and larger 
tumor size (P = 0.039) at the time of diagnosis. Furthermore, in the haplotype analysis of IL-10 gene, we found that 
patients carrying ATA haplotype were in higher LN involvement (p = 0.022) and higher tumor stage(p = 0.028) of breast 
cancer at the time of diagnosis compared with others.
Conclusions: Our findings suggest that IL-10 promoter polymorphisms participate in the progression of breast cancer 
rather than in its initial development in Chinese Han women.
Introduction
Breast cancer is the most common malignancy threaten-
ing the health and life of women and it's incidence has
increased in recent years in both developed and develop-
ing countries[1]. Biologic mechanisms leading to the
development of breast cancer are not clearly understood,
but the role of cytokines in cancer immunity and carcino-
genesis has been well established[2]. As a multifunctional
Th2-cytokine with both immunosuppressive and anti-
angiogenic functions, interleukin-10 (IL-10) may have
both tumor-promoting and tumor-inhibiting proper-
ties[3]. Recent data suggest that polymorphic variations
in the promoter sequences of IL-10 gene may influence
the gene expression[4,5] and consequently play a certain
role in susceptibility and clinical course of breast cancer.
IL-10 is an important immunoregulatory cytokine
mainly produced by activated T cells, monocytes, B cells
and thymocytes. As an immune response modulator, IL-
10 can both stimulate and suppress the immune
response[6]. Numerous studies have shown that IL-10
may be involved in the pathogenesis of cancer, but the
results were inconsistent. On the one hand, increased
serum IL-10 levels could facilitate development of cancer
by suppressing expression of MHC class I and II anti-
gens[7] and preventting tumor antigen presentation to
CD8-cytotoxic T lymphocytes. On the other hand, anti-
angiogenic effects of IL-10 are supposed to play a protec-
tive and preventive role against tumor.
The gene encoding IL-10 is located on human chromo-
some 1q31-1q32[8,9], and is composed of five exons and
four introns. It has been reported that several important
polymorphic sites in the IL-10 gene, including three in
the promoter region (-1082 (A/G, -819 T/C, -592 A/C)
may influence the transcription of IL-10 messenger RNA
and the expression of IL-10 in vitro [10-12]. Although
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several studies have shown the possible involvement of
IL-10 in the pathogenesis of breast cancer, as well as its
association with prognosis in different ethnic popula-
tions, the results were not all consistent[13]. Further-
more, little is known about the effect of these
polymorphisms on the risk of beast cancer in the Han
Chinese population. The goal of this study was to evalu-
ate whether IL-10 gene promoter -1082A/G, -819T/C
and -592A/C polymorphisms and haplotypes were asso-
ciated with breast cancer in a Han Chinese population.
Materials and methods
Subjects
Blood samples were taken from 315 breast cancer cases
and 322 non-cancer controls. The case group was
recruited between October 2008 and October 2009 from
the Shan Dong Cancer Hospital and the PLA 456 Hospi-
tal. The patients' pathological and clinical information
were obtained from their medical files. All cases were
newly diagnosed and previously untreated. The control
group consisted of 322 healthy age-matched women who
visited the general health check-up division at the two
hospitals in the period between October 2008 and Octo-
ber 2009. Selection criteria for controls were no evidence
of any personal or family history of cancer or other seri-
ous illness. At recruitment, each participant was person-
ally interviewed to obtain detailed information on
demographic characteristics and lifetime history of
tobacco and alcohol use. All subjects were unrelated eth-
nic Han Chinese and residents of northern China. The
study has been approved by the Institutional Review
Boards of Shan Dong Cancer Hospital and the PLA 456
Hospital. Written informed consent was obtained from
all participating subjects.
Polymorphism analysis
Genomic DNA was isolated from peripheral blood leuko-
cytes of control subjects and breast cancer patients by the
salting-out method as described previously [14]. Geno-
types were assayed with polymerase chain reactionere-
striction fragment length polymorphism(RFLP) methods.
The PCR primers were designed based on described pre-
viously[15]. The PCR was performed with a 25-μL reac-
tion mixture containing 100 ng of genomic DNA, 0.5
μmol/L of each primer, 200 μmol/L of each dNTP, 2.5U of
Taq DNA polymerase (Omega, Doraville, GA), 10× PCR
buffer supplied by Invitrogen Corp (10 mmol/l Tris-HCl,
pH 8.8, 50 mmol/l KCl), and 2.0 mmol/L MgCl2. The PCR
profile consisted of an initial melting step of 5 minutes at
94°C, followed by 35 cycles of 30 seconds at 94°C, 45 sec-
onds at 58°C for -1082A/G, 59°C for -819 T/C and 62°C
for -592 A/C; 55 s at 72°C; and a final elongation at 72°C
for 8 min. The restriction endonucleases MnlI, MaeIII,
and RsaI (New England Biolabs, Beverly, MA) were used
to distinguish the IL-10 gene -1082A/G, -819T/C, -592A/
C polymorphisms, respectively (Table1). To confirm the
genotyping results, PCR-amplified DNA samples were
examined by DNA sequencing, and the results were 100%
concordant (data not shown).
Statistical analysis
Genotype and allele frequencies of IL-10 were compared
between breast cancer cases and controls by the chi-
squared test or Fisher's exact test when necessary. The
odds rations (OR) and 95% confidence interval (CI) were
calculated to estimate the relative risk conferred by a par-
ticular allele and genotype. Demographic and clinical
data between groups were compared by chi-squared test
and by Student's t-test. Statistical significance was
assumed at the p < 0.05 level. The SPSS for Windows
(version 13.0; SPSS, Inc) was used for all of the statistical
analysis.
Results
Subject characteristics
The demographics of the cases and controls enrolled in
this study are summarized in Table2. There were no sta-
tistically significant differences between the cases and
Table 1: Primer sequences and reaction conditions for genotyping IL-10 polymorphisms
Polymorphism db SNP ID PCR Primer sequence RE Product size(bp)
-1082 A/G Rs1800870 F: 5'-CTCGCTGCAACCCAACTGGC-3'
R: 5'-TCTTACCTATCCCTACTTCC-3'
MnlI G: 106+33
A: 139
-819 T/C Rs1800871 F: 5-TCATTCTATGTGCTGGAGATGG-3'
R: 5'-TGGGGGAAGTGGGTAAGAGT-3'
MaeIII C:125+84
T: 209
-592 A/C Rs1800872 F: 5-GGTGAGCACTACCTGACTAGC-3'
R: 5'-CCTAGGTCACAGTGACGTGG-3'
RsaI A:236+176
C: 412
Abbreviations: dbSNP ID, database identifier; SNP, single-nucleotide polymorphism; PCR, polymerase chain reaction; RE, restriction 
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Table 2: Characteristics of patients with breast cancer and healthy controls
Variable Patients, no. (%) Controls, no. (%) P-value
n = 315 n = 322
Age(year) 0.979
< 48 165 (52.4) 169 (52.5)
≥48 150 (47.6) 153 (47.5)
Menopausal status 0.593
Premenopausal 144 (45.7) 154 (47.8)
Postmenopausal 171 (54.3) 168 (52.2)
Tumor size (cm)
< 2 104 (33.0)
2~5 167 (53.0)
≥5 44 (14.0)
LN involvement
Positive 117 (37.1)
Negative 198 (62.9)
ER expression
Positive 169 (53.7)
Negative 146 (46.3)
PR expression
Positive 166 (52.7)
Negative 149 (47.3)
Table 3: Genotype and allele frequencies of IL-10 promoter polymorphisms in breast cancer patients and healthy controls
Frequency, no.(%) Frequency, no.(%)
Genetype Patients 
n = 315
Controls 
n = 322
P-value Alleles Patients 
2n = 630
Controls 
2n = 644
P-value
-1082 A/G 0.664 -1082 A/G 0.374
AA 285 (90.5) 285 (88.5) A 599 (95.1) 605 (93.9)
AG 29 (9.2) 35 (10.9) G 31 (4.9) 39 (6.1)
GG 1 (0.3) 2 (0.6)
-819 T/C 0.604 -819 T/C 0.315
TT 119 (37.8) 134 (41.6) T 373 (59.2) 399 (62.0)
TC 135 (42.9) 131 (40.7) C 257 (40.8) 245 (38.0)
CC 61 (19.3) 57 (17.7)
-592 A/C 0.604 -592 A/C 0.315
AA 119 (37.8) 134 (41.6) A 373 (59.2) 399 (62.0)
AC 135 (42.9) 131 (40.7) C 257 (40.8) 245 (38.0)
CC 61 (19.3) 57 (17.7)Kong et al. Journal of Experimental & Clinical Cancer Research 2010, 29:72
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controls for the age, menopausal status (P = 0.979 and P =
0.593, respectively), and this suggested that the matching
based on these two variables was adequate.
Genotype and allele frequencies
The genotype and allele frequencies of the IL-10 gene
polymorphisms in breast cancer patients and healthy
controls are show in Table3. The genotypes were found to
be in Hardy-Weinberg equilibrium in both case and con-
trol groups. Statistical analysis, however, revealed no sig-
nificant differences in the genotype and allele frequencies
at all three SNP sites between patients and healthy con-
trols. In addition to overall comparisons, the genotype
frequencies were compared in subgroups classified
according to menopausal status and no association was
found between genotypes and risk of breast cancer.
Analysis of association between genotypes and clinico-
pathologic features of breast cancer revealed no associa-
tion between genotypes at these positions and ER
expression and PR expression. Tumor size was signifi-
cantly different between carriers of the AA genotype at
position -1082 A/G in comparison to other genotypes (P
= 0.039). In addition, LN involvement was significantly
lower in patients harboring at least one G allele at posi-
tion -1082 A/G (AG and GG genotypes) in comparison to
patients with the AA genotype(P = 0.041). (Table4)
Haplotypes analysis
The estimated haplotype frequencies of IL-10 polymor-
phisms in breaste cancer patients and controls are shown
in Table5. Complete linkage disequilibrium was observed
between locus -819T/C and locus -592 A/C. Four possi-
ble haplotypes were demonstrated in our population. The
m os t  fr equ e n t  ha pl ot ype in bot h pa t ie n ts a nd c on t r ols
was ATA haplotype(harboring wild type alleles of all
three positions and with 56.5% frequency in patients vs.
Table 4: Genotype frequencies of IL-10 and clinicopathologic features of breast cancer patients
Clinicopathologic 
features
n Genetype (%) χ2 p
AA AG+GG
ER expression 0.001 0.971
Positive 169 153 (90.5) 16 (9.5)
Negative 146 132 (90.4) 14 (9.6)
PR expression 0.209 0.647
Positive 166 149 (89.8) 17 (10.2)
Negative 149 136 (91.3) 13 (8.7)
Tumor size (cm) 6.471 0.039
< 2 104 88 (84.6) 16 (15.4)
2~5 167 155 (92.8) 12 (7.2)
≥5 44 42 (95.5) 2 (4.5)
LN involvement 4.174 0.041
Negative 198 174 (87.9) 24 (12.1)
Positive 117 111 (94.9) 6 (5.1)
Table 5: Frequencies of IL-10 Haplotypes(-1082, -810, -592) in breast cancer patients and healthy controls
Patients, no. (%) Controls, no. (%)
Possible haplotype 2n = 630 2n = 644 χ2 P-value
ATA 356 (56.5) 377 (58.5) 1.857 0.603
ACC 243 (38.6) 228 (35.4)
GTA 17 (2.7) 22 (3.4)
GCC 14 (2.2) 17 (2.6)Kong et al. Journal of Experimental & Clinical Cancer Research 2010, 29:72
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58.5% in controls). The frequencies of haplotype were
investigated and no significant differences were observed
between patients and healthy controls.
Analysis of breast cancer prognostic and predictive fac-
tors revealed that ATA haplotype was associated with a
significantly increased risk of lymph node metastasis at
t h e  t i m e  o f  d i a g n o s i s  a s  c o m p a r e d  w i t h  o t h e r  h a p l o -
types(P = 0.022). In addition, we also found strong associ-
ation between tumor size and the ATA haplotypes(P =
0.028). (Table6)
Discussion
In this case-control study we evaluated the association
between the polymorphisms of the IL-10 promoter and
breast cancer in a Han Chinese population. Our data did
not show significant differences in allele, genotype and
haplotype frequencies between breast cancer patients
and healthy controls. In concordance with our study,
Howell et al.[16], Smith et al. [17] and Balasubramanian
et al.[18] reported that there were no apparent relation-
ship of the IL-10 gene promoter polymorphisms with the
risk of breast cancer. However, these results are not con-
sistent with the study conducted in Austrian previously,
in which the -592AA genotype was shown to be associ-
ated with a reduced breast cancer risk[19]. Moreover,
another study from the Italian population showed that
the IL-10 -1082AA genotype was correlated with a
marked increase in breast cancer risk[20]. Although it is
difficult to determine the reasons behind the contradic-
tory results in these studies, the different genetic back-
ground of study population may be one of the main
factors.
In this study, we found that the frequencies of the -1082
G, -819 C and -592 C alleles among the healthy controls
(0.061, 0.380 and 0.380, respectively) were similar to
those observed in an Asian population[21,22] but signifi-
cantly lower than those of European Caucasians [23-25].
We also found that there was strong linkage disequilib-
rium among the -1082A/G, -819 T/C and -592 A/C poly-
morphisms. Complete linkage disequilibrium was
observed between locus -819T/C and locus -592 A/C.
Four possible haplotypes were demonstrated in our pop-
ulation. Major haplotype frequency of the ATA among
the controls in the present study was 0.585, which was
significantly higher than those of study performed in the
European Caucasians (0.290 and 0.248, respec-
tively)[24,26]. These results suggest that the frequencies
of IL-10 gene alleles and haplotypes might vary among
the different ethnic population.
Although we did not find an association of the IL-10
gene polymorphisms with risk of breast cancer, in present
study we reported for the first time that the IL-10 pro-
moter haplotypes and -1082 A/G polymorphism were
significantly associated with the prognostic and predic-
tive factors of breast cancer in Chinese han women. Our
data showed that the -1082AA genotype was associated
with a significantly increased risk of lymph node (LN)
involvement (P = 0.041) and larger tumor size (P = 0.039)
at the time of diagnosis. Moreover, in the haplotype anal-
ysis of IL-10 gene, we also found that patients carrying
Table 6: Frequencies of IL-10 Haplotypes(-1082, -810, -592) and clinicopathologic features of breast cancer patients
haplotype (%)
Clinicopathologic 
features
2n ATA non-ATA χ2 p
ER expression 0.026 0.872
Positive 338 192 (56.8) 146 (43.2)
Negative 292 164 (56.2) 128 (43.8)
PR expression 0.010 0.922
Positive 332 187 (56.3) 145 (43.7)
Negative 298 169 (56.7) 129 (43.3)
Tumor size (cm) 7.180 0.028
< 2 208 105 (50.5) 103 (49.5)
2~5 334 192 (57.5) 142 (42.5)
≥5 88 59 (67.0) 29 (33.0)
LN involvement 5.246 0.022
Negative 396 210 (53.0) 186 (47.0)
Positive 234 146 (62.4) 88 (37.6)Kong et al. Journal of Experimental & Clinical Cancer Research 2010, 29:72
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ATA haplotype were in higher LN involvement (p  =
0.022) and higher tumor stage(p = 0.028) of breast cancer
at the time of diagnosis compared with others. The find-
ings suggest that the IL-10 ATA haplotype and -1082AA
genotype might be adverse prognostic factors in breast
cancer in Chinese Han women.
IL-10 is a multifunctional cytokine with both immuno-
suppressive and antiangiogenic functions, which may
play varied roles in the pathogenesis and development of
breast cancer. Although the genetic control of IL-10
expression is not clearly understood yet, polymorphisms
in promoter have been reported to determine interindi-
vidual differences in IL-10 production[4,9]. Previous
studies indicated that IL-10 promoter -1082 AA genotype
was associated with decreased IL-10 expression[27]. ATA
haplotype formed by polymorphisms at positions -1,082,
-819 and -592 in the promoter of the IL-10 gene has been
is generally assumed to be a lower IL-10 responder[10-
12]. This and the present study indicate that low levels of
IL-10 may play a facilitative role in the development of
breast cancer. Findings of our study are further supported
by a recent study showing that the low-expression allele
and haplotype were associated with reduced disease-free
survival and the IL-10 gene polymorphisms may be a
potential prognosis marker in breast cancer for disease-
free survival[28]. The mechanism for this remains
unclear, but may likely include anti-angiogenic functions
of IL-10.
In conclusion, in this case-control study, we report for
the first time that the IL-10 promoter polymorphisms
were significantly associated with the prognostic and pre-
dictive factors of breast cancer in a Chinese han popula-
tion. The main finding of our study suggests that IL-10
promoter polymorphisms participate in the progression
of breast cancer rather than in its initial development.
Considering limited sample size, nonrandom sampling
and pitfalls of unknown confounders, further studies with
larger sample size from different ethnic origins are
required to confirm and extend our observations. In
addition, more studies should be carried out to clarify the
exact molecular mechanism of IL-10 polymorphisms
effects.
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